Baudax Bio Inc (BXRX) Stock
BXRX is no longer traded. Baudax Bio Inc was delisted from the Nasdaq in April 2024.
Prices on this page are historical; the last trade was April 29, 2024 at $0.01.
Baudax Bio Inc stock price history
BXRX final trading statistics
- Final close
- $0.01
- Final trading day
- Apr 29, 2024
- Market cap at delisting
- $950.3K
- Shares outstanding
- 43.59M
- Final 52-week range
- $0.01 – $1.43
- Avg. volume (final 3 mo.)
- 147,983
- All-time high (split-adj.)
- $1000000.00 · Nov 2019
- All-time low (split-adj.)
- $0.01 · Apr 2024
- Return since IPO
- -100.0%
- Beta
- 1.58
- Book value / share
- -$0.84
- Price / book
- -0.01
Baudax Bio Inc annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $1.27M | -$7.2M | — |
| FY2022 | $1.27M | -$58.8M | -$207.53 |
| FY2021 | $1.08M | -$19.8M | -$578.80 |
| FY2020 | $493.0K | -$76.1M | -$7728.00 |
| FY2019 | $349.0K | -$18.0M | -$1094.76 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Baudax Bio Inc
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania. On February 22, 2024, Baudax Bio, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of Pennsylvania.
Baudax Bio Inc stock FAQ
What happened to Baudax Bio Inc stock?
Baudax Bio Inc stock was delisted from the Nasdaq. Its final close was $0.01 on April 29, 2024.
Is BXRX stock still trading?
No. BXRX was delisted from the Nasdaq in April 2024 and no longer trades on a U.S. exchange.
What was the last price of BXRX stock?
BXRX closed at $0.01 on its final trading day, April 29, 2024, for a market value of about $950.3K.
What were Baudax Bio Inc's revenue and earnings in its last full fiscal year?
Baudax Bio Inc reported revenue of $1.27M and net income of -$7.2M in fiscal 2023, its last full year as a public company.
When did Baudax Bio Inc go public?
Baudax Bio Inc stock began trading on November 22, 2019.